PRP vs PRF in Management of Striae Distensae

April 30, 2026 updated by: Mona El Radi Kamal Mohamed Emam, Zagazig University

Split-Side Comparative Clinical Study of Platelet-Rich Fibrin Versus Platelet-Rich Plasma With or Without Microneedling in Treatment of Striae Distensae

A split-side comparative clinical study evaluating the efficacy and safety of injectable platelet-rich fibrin (PRF) versus platelet-rich plasma (PRP), alone or combined with microneedling, in the treatment of striae distensae. Thirty patients received PRF or PRP on one side and combination therapy with microneedling on the contralateral side over five sessions. Outcomes included striae width, length, severity score, and patient satisfaction

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Zagazig--
      • Zagazig, Zagazig--, Egypt, 44519
        • Zagazig university hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults ≥18 years
  • Presence of striae distensae (rubrae or alba)
  • Willingness to participate and provide informed consent

Exclusion Criteria:

  • Keloid or hypertrophic scar tendency
  • Bleeding disorders or anticoagulant use
  • Pregnancy
  • Active skin infections (e.g., herpes, impetigo, tinea)
  • History of malignancy or collagen disease
  • Use of antineoplastic drugs
  • Conditions impairing wound healing
  • Unrealistic expectations

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: PRF
Intradermal injection of platelet-rich fibrin
Biological: PRF group
Autologous platelet-rich fibrin prepared via single-spin centrifugation without anticoagulant and injected intradermally
Active Comparator: PRP
Intradermal injection of platelet-rich plasma
Biological: PRP injection
Intradermal injection of platelet-rich plasma
Active Comparator: PRF and Microneedling
Microneedling followed by topical PRF application
Device: PRF and microneedling
Performed using a dermapen device with 1 mm needle depth, followed by topical application of PRF.
Active Comparator: PRP and microneedling
Device: PRP and microneedling
Performed using a dermapen device with 1 mm needle depth, followed by topical application of PRP.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Imam, Nelva, Alviera score (INA score) (Change in striae severity)
Time Frame: baseline to 1 month after last session
The INA score ranges from 0 to 54, with higher scores indicating greater striae distensae severity, therefore representing a worse outcome. Severity was categorized as mild for scores <21, moderate for scores 21-40, and severe for scores >40.
baseline to 1 month after last session
Change in striae severity (Imam, Nelva, Alviera score (INA score)
Time Frame: 1 month after last session
The INA score ranges from 0 to 54, with higher scores indicating greater striae distensae severity, therefore representing a worse outcome. Severity was categorized as mild for scores <21, moderate for scores 21-40, and severe for scores >40.
1 month after last session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zagazig University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2024

Primary Completion (Actual)

September 25, 2025

Study Completion (Actual)

February 17, 2026

Study Registration Dates

First Submitted

April 25, 2026

First Submitted That Met QC Criteria

April 25, 2026

First Posted (Actual)

May 1, 2026

Study Record Updates

Last Update Posted (Actual)

May 7, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 11345-3-12-2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Striae Distensae

Clinical Trials on PRF group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe